Shufro Rose & CO LLC Salarius Pharmaceuticals, Inc. Transaction History

Shufro Rose & CO LLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Jul 22, 2022	SELL	$0.16 - $0.42 $2,624 - $6,888	-16,400 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$0.34 - $0.54 $5,576 - $8,856	16,400 New	16,400 $7,000

Ticker SLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,244,650
Market Cap $3.37M
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...

Get notified when there are updates to the investment portfolio of Shufro Rose & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Shufro Rose & CO LLC with notifications on news.